Erythropoietin-induced recurrent veno-occlusive priapism associated with end-stage renal disease.
This is the first report of a male hemodialysis patient experiencing recurrent dialysis-associated priapism that resolved when his concurrent erythropoietin dose was reduced from 2000 to 1500 U one time per week and held if his hemoglobin was greater than 10 g/dL. We discuss dialysis-associated priapism and the effects of erythropoietin on the coagulation cascade and male hormone levels in an effort to elucidate the etiology of priapism in this patient.
Brown
J A
JA
Department of Urology, Mayo Clinic, Rochester, Minnesota 55901, USA.
Nehra
A
A
D000328:Adult; D004921:Erythropoietin / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D011317:Priapism / Q000209:etiology*; D012008:Recurrence; D006435:Renal Dialysis / Q000009:adverse effects*
D004921:Erythropoietin